Recognising the challenges of implementing multi-centre adaptive plan of the day radiotherapy.

Adaptive Bladder cancer Education IGRT Plan selection Quality assurance

Journal

Technical innovations & patient support in radiation oncology
ISSN: 2405-6324
Titre abrégé: Tech Innov Patient Support Radiat Oncol
Pays: England
ID NLM: 101762366

Informations de publication

Date de publication:
Mar 2022
Historique:
received: 29 11 2021
revised: 24 01 2022
accepted: 26 01 2022
entrez: 24 2 2022
pubmed: 25 2 2022
medline: 25 2 2022
Statut: epublish

Résumé

Two multicentre adaptive radiotherapy trials utilising Plan of the Day (PoD) with a library of plans were introduced in 35 centres. The common issues that arose from all centres when introducing PoD were collated retrospectively, through reviewing the data pertaining to the pre-trial and on-trial quality assurance programme. It was found that 1,295 issues arose when introducing PoD in outlining, planning, treatment delivery i.e., PoD selection, and in the overall process of delivering PoD. There was no difference in the number of issues that arose from pre-trial to on-trial. Thus, it is recommended that the implementation of PoD is supported by guidance, reviews, and continuous monitoring.

Identifiants

pubmed: 35198744
doi: 10.1016/j.tipsro.2022.01.002
pii: S2405-6324(22)00002-6
pmc: PMC8841376
doi:

Types de publication

Journal Article

Langues

eng

Pagination

31-35

Informations de copyright

© 2022 The Authors.

Déclaration de conflit d'intérêts

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Shaista Hafeez: SH acknowledges support from the National Institute for Health Research (NIHR) Biomedical Research Centre at The Royal Marsden NHS Foundation Trust and the Institute of Cancer Research, London. SH reports non-financial support from Elekta (Elekta AB, Stockholm, Sweden), non- financial support from Merck Sharp & Dohme (MSD), personal fees and non-financial support from Roche outside the submitted work. Emma Hall: EH declares grant funding to Institution from Cancer Research UK; grant funding to Institution from Accuray Inc. and Varian Medical Systems Inc. outside the submitted work. Other authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Références

Radiother Oncol. 2020 Dec;153:88-96
pubmed: 32579998
Clin Oncol (R Coll Radiol). 2021 Jul;33(7):461-467
pubmed: 33766503
Radiother Oncol. 2020 Dec;153:79-87
pubmed: 32585236
Radiother Oncol. 2012 Oct;105(1):4-8
pubmed: 22985777
Tech Innov Patient Support Radiat Oncol. 2019 Jun 22;10:8-12
pubmed: 32095541
J Clin Oncol. 2010 Jun 20;28(18):2996-3001
pubmed: 20479390
Radiat Oncol. 2017 Nov 15;12(1):179
pubmed: 29141663
Radiat Oncol. 2020 Jan 13;15(1):13
pubmed: 31931829
Acta Oncol. 2017 May;56(5):667-674
pubmed: 28447562
BMJ Open. 2020 Dec 31;10(12):e041005
pubmed: 33384390
BMJ Open. 2020 May 26;10(5):e037134
pubmed: 32461298
Radiat Oncol. 2019 Jun 13;14(1):105
pubmed: 31196120
Clin Transl Radiat Oncol. 2019 Jul 24;19:27-32
pubmed: 31388568
Front Oncol. 2019 Aug 21;9:792
pubmed: 31497534

Auteurs

Amanda Webster (A)

National Radiotherapy Trials Quality Assurance Group (RTTQA), University College Hospital (UCLH), London, United Kingdom.

Helen A McNair (HA)

Division of Radiotherapy and Imaging, Institute of Cancer Research, London, United Kingdom.
The Royal Marsden NHS Foundation Trust, Radiotherapy Department, London, United Kingdom.

Vibeke N Hansen (VN)

Copenhagen University Hospital -Rigshospitalet, Department of Oncology, Copenhagen, Denmark.

Rebecca Lewis (R)

Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, United Kingdom.

Emma Patel (E)

National Radiotherapy Trials Quality Assurance Group (RTTQA), University College Hospital (UCLH), London, United Kingdom.

Elizabeth Miles (E)

National Radiotherapy Trials Quality Assurance Group (RTTQA), Mount Vernon Hospital, Northwood, United Kingdom.

Emma Hall (E)

Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, United Kingdom.

Shaista Hafeez (S)

Division of Radiotherapy and Imaging, Institute of Cancer Research, London, United Kingdom.
The Royal Marsden NHS Foundation Trust, Radiotherapy Department, London, United Kingdom.

Robert Huddart (R)

Division of Radiotherapy and Imaging, Institute of Cancer Research, London, United Kingdom.
The Royal Marsden NHS Foundation Trust, Radiotherapy Department, London, United Kingdom.

Classifications MeSH